Oncolytics (ONCY) Biotech announced that Germany’s medical regulatory body, the Paul-Ehrlich-Institute, has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in newly diagnosed pancreatic ductal adenocarcinoma patients. Following a positive safety review by the independent Data Safety Monitoring Board, which recommended continuation, the PEI’s approval allows Cohort 5 to progress to full enrollment. Early safety data will be presented at the upcoming 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium later this month, with initial efficacy results expected in the second half of the year.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Biotech Alert: Searches spiking for these stocks today
- Oncolytics Biotech Reports Promising Cancer Study Results
- Oncolytics Biotech Unveils Promising Cancer Therapy Results
- Oncolytics Biotech Progresses with GOBLET Cancer Trial
- Oncolytics: DSMB recommended continued enrollment in Cohort 5 of GOBLET study